Gossamer Bio ( (GOSS) ) has released its Q3 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing and commercializing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company operates in the biopharmaceutical sector, with a unique focus on pulmonary hypertension therapies.
In its latest earnings report, Gossamer Bio announced its financial results for the third quarter of 2025 and provided a business update. Key highlights include the expected topline results from the PROSERA Phase 3 study in February 2026 and the activation of the first site for the Phase 3 SERANATA study in PH-ILD.
Gossamer Bio reported cash, cash equivalents, and marketable securities totaling $180 million as of September 30, 2025. The company’s revenue from contracts with collaborators reached $13.3 million, while research and development expenses increased to $45.5 million. The net loss for the quarter was $48.2 million, reflecting ongoing investments in clinical trials and research.
Strategically, Gossamer Bio has entered a strategic option agreement to acquire Respira Therapeutics Inc., which could enhance its portfolio with an inhaled formulation of vardenafil for pulmonary hypertension. This move is designed to minimize near-term cash burn and preserve financial stability.
Looking ahead, Gossamer Bio remains focused on advancing its clinical trials and expects its current financial resources to fund operations into 2027. The company is optimistic about the potential impact of its therapies on patients with PAH and PH-ILD, aiming to improve patient outcomes through innovative treatments.